Clinical Trials Logo
  1. Home
  2. Classic Hodgkin Lymphoma
  3. NCT06377540

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma Clinical Trial

Official title:
MT2022-60: A Phase II Study of Pembrolizumab+ BEAM Conditioning Regimen Before Autologous Stem Cell Transplant (ASCT) Followed by Pembrolizumab Maintenance in Patients of Relapsed or Refractory Classic Hodgkin Lymphoma

Clinical Trial Summary

This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06377540
Study type Interventional
Source Masonic Cancer Center, University of Minnesota
Contact Sanjal Desai
Phone 612-625-5469
Email desai171@umn.edu
Status Not yet recruiting
Phase Phase 2
Start date August 1, 2024
Completion date September 1, 2027
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03233347 - Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma Phase 2
Active, not recruiting NCT03712202 - Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Phase 2
Recruiting NCT05833984 - Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Active, not recruiting NCT02758717 - Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Phase 2
Active, not recruiting NCT01771107 - Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT02166463 - Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma Phase 3
Completed NCT00654732 - Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma Phase 2
Active, not recruiting NCT04788043 - Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma Phase 2
Not yet recruiting NCT06465446 - A Study of IMM01 in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma Phase 3
Recruiting NCT05955105 - A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies Phase 1/Phase 2
Completed NCT06235047 - Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)
Recruiting NCT06164275 - Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Phase 2
Active, not recruiting NCT05179603 - A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] Phase 2
Active, not recruiting NCT03907488 - Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Phase 3
Not yet recruiting NCT05949931 - Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma Phase 2
Active, not recruiting NCT03057795 - Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma Phase 2